Backer Marianne De Sells 19,039 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 19,039 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $7.45, for a total value of $141,840.55. Following the completion of the transaction, the chief executive officer owned 1,035,466 shares in the company, valued at approximately $7,714,221.70. This represents a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vir Biotechnology Trading Up 5.4%

Vir Biotechnology stock opened at $10.00 on Thursday. The company has a market cap of $1.40 billion, a PE ratio of -3.16 and a beta of 1.69. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.94. The company’s 50-day moving average is $6.88 and its two-hundred day moving average is $6.02.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The company had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. During the same quarter in the previous year, the company earned ($0.76) EPS. Vir Biotechnology’s revenue was up 417.8% on a year-over-year basis. Research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Barclays lifted their price objective on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price for the company in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Evercore reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a research note on Tuesday. Finally, Needham & Company LLC increased their target price on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.88.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas collaboration materially de‑risks and commercializes VIR‑5500 — Astellas agreed to a global co‑development/co‑commercialization partnership with ~$335M upfront and up to ~$1.37B in milestones, validating the program and providing near‑term cash and regulatory/commercial heft. Read More.
• Positive Sentiment: Updated Phase‑1 VIR‑5500 data supportive — The company reported a favorable safety profile and meaningful activity (higher‑dose ORR ≈45%), which underpins the Astellas deal valuation and pipeline upside. Read More.
• Positive Sentiment: Q4 results beat revenue estimates — Vir reported EPS better than street loss expectations and revenue (~$64.1M) well above consensus, showing stronger near‑term commercial performance and improving investor confidence. Read More.
• Positive Sentiment: Analyst upgrades / price‑target increases — Several firms raised or reiterated buy ratings and lifted targets (Needham moved its PT higher), which supports further upside momentum. Read More.
• Neutral Sentiment: Widespread media coverage amplifies visibility and volume but doesn’t change fundamentals by itself — extensive press (Forbes, Seeking Alpha, MSN) is driving retail interest and heavier trading. Read More.
• Neutral Sentiment: Company disclosures provide more modeling detail — the earnings transcript and slides give updated cash, pipeline and milestone assumptions for valuation work. Read More.
• Negative Sentiment: Proposed public offering announced — management filed to sell additional common stock; proceeds would boost the balance sheet but dilute existing holders and can pressure the stock near term. Read More.
• Negative Sentiment: Insider selling by multiple senior executives — CEO and several officers disclosed sales on Feb. 23; while sales can be for personal reasons, clustered insider dispositions can signal sentiment and add supply into the market. Read More.
• Negative Sentiment: Large net losses and negative margins remain — despite revenue growth and partnerships, Vir’s significant 2025 net loss means future stock performance depends on execution, milestones and successful commercial roll‑outs. Read More.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in VIR. ARCH Venture Management LLC acquired a new position in Vir Biotechnology in the 2nd quarter worth $65,100,000. GSK plc bought a new stake in shares of Vir Biotechnology in the fourth quarter valued at about $51,562,000. State Street Corp boosted its position in shares of Vir Biotechnology by 18.9% during the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after buying an additional 988,262 shares during the period. Orbimed Advisors LLC grew its holdings in shares of Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after buying an additional 132,466 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Vir Biotechnology by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock valued at $14,041,000 after buying an additional 81,985 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.